drugset / Trial / NCT00904098

Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine

NCT00904098

Phase 4 Completed 192 enrolled Endo USA Inc., a Keenova Therapeutics Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Females 18 years of age or older with at least one year history of menstrual migraine (MM) headaches participated in a Phase 4 clinical trial to evaluate the efficacy of frovatriptan when used at the early stage (International Headache Society \[IHS\] Grade 1) of MM compared with patients' current treatment.

Timeline

Start
2005-09
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Frovatriptan Small molecule 2.5 mg Oral

Indications